A Moderate to Severe Rheumatoid Arthritis Study

Inclusion Criteria:

• Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the AmericanCollege of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteriafor the Classification of RA

• Have moderately to severely active RA defined as the presence of at least 6/68 tenderjoints and at least 6/66 swollen joints

• Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP)measurement ≥ (greater than or equal to) 1 times the upper limit of normal (ULN)

• Have been treated at approved doses with at least 1 biologic tumor necrosis factor (TNF)- alpha inhibitor for at least 3 months and either:

• experienced insufficient efficacy or loss of efficacy

• experienced intolerance of such treatment

• Have had regular use of at least 1 conventional disease-modifying antirheumatic drugs (cDMARD) for at least the 12 weeks prior to study entry with a continuous, nonchangingdose for at least 8 weeks prior to study entry

Exclusion Criteria:

• Have received a biologic treatment for RA within 28 days of planned randomization;have received rituximab within 6 months of planned randomization

• Are currently receiving corticosteroids at doses > (greater than) 10 mg per day ofprednisone (or equivalent) or have been receiving an unstable dosing regimen ofcorticosteroids within 2 weeks of study entry or within 6 weeks of plannedrandomization

• Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or havebeen receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry orwithin 6 weeks of planned randomization

• Are currently receiving concomitant treatment with methotrexate (MTX),hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs

• Have received any parenteral corticosteroid administered by intramuscular orintravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks priorto planned randomization or are anticipated to require parenteral injection ofcorticosteroids during the study

• Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronicacid within 2 weeks prior to study entry or within 6 weeks prior to plannedrandomization

• Have active fibromyalgia that, in the investigator's opinion, would make it difficultto appropriately assess RA activity for the purposes of this study

• Have a diagnosis of any systemic inflammatory condition other than RA, such as, butnot limited to juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,ulcerative colitis, psoriatic arthritis, active vasculitis or gout (participants withsecondary Sjogren's syndrome are not excluded.)

• Have a diagnosis of Felty's syndrome

• Have had any major surgery within 8 weeks of study entry or will require major surgeryduring the study that, in the opinion of the investigator in consultation with Lillyor its designee, would pose an unacceptable risk to the participant

• Have experienced any of the following within 12 weeks of study entry: myocardialinfarction, unstable ischemic heart disease, stroke, or have New York HeartAssociation stage IV heart failure

• Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,endocrine, hematological, neurological, or neuropsychiatric disorders or any otherserious and/or unstable illness that, in the opinion of the investigator, couldconstitute a risk when taking investigational product or could interfere with theinterpretation of data

• Are largely or wholly incapacitated permitting little or no self care, such as, beingbedridden or confined to a wheelchair

• Have an estimated glomerular filtration rate (eGFR) based on the most recent availableserum creatinine using the Modification of Diet in Renal Disease (MDRD) method of < (less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)

• Have a history of chronic liver disease with the most recent available aspartateaminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or themost recent available total bilirubin ≥1.5 times the ULN

• Have a history of, lymphoproliferative disease; or have signs or symptoms suggestiveof possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; orhave active primary or recurrent malignant disease; or have been in remission fromclinically significant malignancy for <5 years

• Have been exposed to a live vaccine within 12 weeks prior to planned randomization orare expected to need/receive a live vaccine during the course of the study (with theexception of herpes zoster vaccination)

• Have a current or recent clinically serious viral, bacterial, fungal, or parasiticinfection

• Have had symptomatic herpes zoster infection within 12 weeks prior to study entry

• Have a history of disseminated/complicated herpes zoster (eg, multidermatomalinvolvement, ophthalmic zoster, central nervous system involvement, postherpeticneuralgia)

• Are immunocompromised and, in the opinion of the investigator, are at an unacceptablerisk for participating in the study

• Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or humanimmunodeficiency virus (HIV)

• Have screening laboratory test values, including thyroid-stimulating hormone (TSH),outside the reference range for the population or investigative site that, in theopinion of the investigator, pose an unacceptable risk for the participant'sparticipation in the study

• Have screening electrocardiogram (ECG) abnormalities that, in the opinion of theinvestigator or the sponsor, are clinically significant and indicate an unacceptablerisk for the participant's participation in the study (e.g. Fridericia's corrected QTinterval >500 millisecond [msec])

• Have symptomatic herpes simplex at the time of study enrollment

• Have evidence of active or latent tuberculosis (TB)